Showing results 1 to 2 of 2
| Issue Year | Title | Author(s) | Type | Views | Downloads |
|---|---|---|---|---|---|
| 2023 | KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC | Ren, S.; Feng, J.; Ma, S.; Chen, H.; Ma, Z.; Huang, C.; Zhang, L.; He, J.; Wang, C.; Zhou, J.; Danchaivijitr, P.; Wang, C.-C.; Vynnychenko, Ihor Oleksandrovych; Wang, K.; Orlandi, F.; Sriuranpong, V.; Li, B.; Ge, J.; Dang, T.; Zhou, C. | Article | 725 | 71 |
| 2020 | Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033 | Zhou, C.; Feng, S.; Ma, S.; Chen, H.; Ma, Z.; Huang, C.; Zhang, L.; He, J.; Wang, C.; Zhou, J.; Danchaivijtr, P.; Huang, H-C.; Vynnychenko, Ihor Oleksandrovych; Wang, K.; Orlandi, F.; Sriuranpong, V.; Li, B.; Ge, J.; Dang, T. | Conference Papers | 1963732892 | 112788198 |